ArticleCureus2025
Long-Term Abdominal Drains in Refractory Ascites Due to Cirrhosis: A Retrospective Cohort Analysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRefractory ascites in cirrhosis presents major management challenges and is associated with frequent hospital admissions, reduced quality of life, and poor survival. Long-term abdominal drains (LTADs) have emerged as a palliative alternative to repeated large-volume paracentesis (LVP), yet real-world outcome data remain limited.
methodsWe performed a retrospective analysis of 44 patients with cirrhosis and refractory ascites who underwent LTAD insertion between 2019 and 2024 at a district general hospital. Clinical outcomes, including survival, complication rates, hospital admissions, and length of stay (LOS), were evaluated. Data were analysed using Kaplan-Meier survival curves and descriptive statistics for pre- and post-LTAD comparisons.
resultsMedian survival after LTAD was eight months; Kaplan-Meier estimated 12-month survival was 65%. LTAD insertion was associated with a 47% reduction in hospital admissions and a 55% reduction in cumulative LOS in the six months post-procedure compared to the six months pre-procedure. Specifically, admissions dropped from 102 to 54, and LOS from 1,150 to 520 days for the cohort. Spontaneous bacterial peritonitis (SBP) occurred in 18% of patients and catheter-related infections in 11%. Ascitic fluid leakage was observed in 20% and drain blockage in 14%. No procedure-related mortality was identified.
conclusionLTADs represent a safe and effective palliative strategy for managing refractory ascites in cirrhosis. They significantly reduce healthcare utilisation while maintaining acceptable complication rates. Careful patient selection and multidisciplinary management are essential to optimise outcomes. LTADs are currently a case-by-case palliative option, but ongoing trials will further clarify their role. Prospective studies are warranted to validate these findings and to assess quality-of-life improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.